Future Market Insights.png
Clinical Trials Market to Surpass US$ 177.7 Billion Valuation by 2033 Owing to the Development of Precision Medicines and Therapeutic Approaches | Future Market Insights, Inc. NEWARK, Del, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The global Clinical Trials Market is anticipated to augment at a flourishing CAGR of 4.41% over the forecast period from 2023 to 2033. The global...
Clinical ink Selecte
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
14 déc. 2022 10h47 HE | Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
Featured Image for POP Biotechnologies
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
30 nov. 2022 15h01 HE | POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
AMR Logo.png
Patient Registry Software Market is Expected to Reach USD 2.50 Bn by 2031: Allied Market Research
10 oct. 2022 12h30 HE | Allied Market Research
Portland, OR, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Global Patient Registry Software Market generated $993.3 million in 2021, and is...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE | POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
radiomedix logo
18 nov. 2021 17h00 HE | RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...
Algernon Logo 1.png
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
13 oct. 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Dermavant Logo Color Sig (002).png
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
03 déc. 2019 08h00 HE | Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
Eko Home
Eko Launches ‘Eko Home,' a Cardiac Remote Monitoring Application Enabling Powerful Drug-Data Combinations to Enhance Clinical Studies and Pharmaceutical Trials
25 juil. 2019 13h00 HE | Eko
San Francisco, July 25, 2019 (GLOBE NEWSWIRE) -- Eko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced Eko Home, a...
Endonovo Therapeutics Hires David Clark as Vice President of Sales
03 mai 2019 09h20 HE | Endonovo Therapeutics, Inc.
Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new...